Indication
Refractory Primary Mediastinal Large B-Cell Lymphoma
8 clinical trials
10 products
7 drugs
Clinical trial
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Status: Active (not recruiting), Estimated PCD: 2021-09-24
Drug
AN0025Product
EtoposideProduct
IfosfamideProduct
LenalidomideDrug
VarlilumabClinical trial
Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin LymphomaStatus: Not yet recruiting, Estimated PCD: 2026-01-31
Product
Axicabtagene CiloleucelClinical trial
A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaStatus: Recruiting, Estimated PCD: 2024-12-28
Product
Loncastuximab TesirineProduct
MosunetuzumabDrug
cyclophosphamideDrug
fludarabineClinical trial
A Phase II Trial of Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Pilot Study of Anakinra to Mitigate CAR-T Toxicity in Subjects With Relapsed or Refractory Large B-Cell LymphomaStatus: Completed, Estimated PCD: 2024-05-28
Product
AnakinraDrug
TafasitamabClinical trial
A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells TherapyStatus: Active (not recruiting), Estimated PCD: 2023-01-10
Product
ObinutuzumabDrug
glofitamabClinical trial
A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells Bearing a Human Binding Domain, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Acute Lymphocytic LeukemiaStatus: Terminated, Estimated PCD: 2023-03-23
Clinical trial
A Phase I/II Open Label, Single Center, Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients With Indolent and Aggressive B-Cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2026-03-10
Product
CD47 Antagonist ALX148Drug
lenalidomide